Primary immunodeficiency diseases due to defects in lymphocytes.
about
New strategies in chronic lymphocytic leukemia: shifting treatment paradigmsPrimary immunodeficiencies of pattern recognition receptorsHighly efficient endogenous human gene correction using designed zinc-finger nucleasesHuman lymphoid development in the absence of common γ-chain receptor signaling.A novel functional rabbit IL-7 isoform.Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiencyJak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency.Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.Abnormalities of thymic stroma may contribute to immune dysregulation in murine models of leaky severe combined immunodeficiency.Identification of the earliest natural killer cell-committed progenitor in murine bone marrowEfficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiencyTargeting the Jak/STAT pathway for immunosuppression.A new modality for immunosuppression: targeting the JAK/STAT pathway.Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients.Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age.Molecular defects in T- and B-cell primary immunodeficiency diseases.Cellular calibrators to quantitate T-cell receptor excision circles (TRECs) in clinical samples.Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.Cartilage Hair Hypoplasia: First report from IranPersistent lymphopenia is a risk factor for ICU-acquired infections and for death in ICU patients with sustained hypotension at admission.Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.Targeting kinases for the treatment of inflammatory diseases.Recent advances in transplantation for primary immune deficiency diseases: a comprehensive review.Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects.Genetic variation in pattern recognition receptors: functional consequences and susceptibility to infectious disease.Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.Primary immunodeficiency diseases: dissectors of the immune system.Anti-apoptotic signaling by the interleukin-2 receptor reveals a function for cytoplasmic tyrosine residues within the common gamma (gamma c) receptor subunit.Identification of potential therapeutic target genes, key miRNAs and mechanisms in acute myeloid leukemia based on bioinformatics analysis.Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.Genesis of progressive T-cell deficiency owing to a single missense mutation in the common gamma chain gene.Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.Managing space and marking time: mothering severely ill infants in hospital isolation.
P2860
Q26828496-56EF4EE1-544D-4AC0-9FB6-BA573252BE81Q26828952-9779E2C8-0048-450E-B8FA-3B4B540FFA24Q28243157-6100E611-E157-454A-9E24-64814ECC10F3Q33736960-E6679B26-F798-4BF5-9F88-0995B777B5A5Q33857243-931405D5-5675-44B0-89DC-E3FB4FAB6BEBQ34098712-80B57221-BA41-4DE1-91F8-9BB6661051A8Q34112793-003ABD01-E83E-4B2F-9211-6909BE432095Q34386311-5A96D6C5-EA95-496E-9C2D-CD5B88E30875Q34627045-2607C9EB-82E2-4783-8E96-79D5EE40C81CQ34647002-1B69D416-8517-4C36-90A2-557D35F039E0Q35147048-62BAAECE-3581-436A-9856-86FF6BCB927AQ35553308-19B47700-3579-49F0-8A37-F3F23B8EECA3Q35566525-2CD7634A-3BC3-457D-BA92-9F88D29385B5Q35579377-6C053E79-B523-4A22-AF87-C8F7C8A86EC4Q35825869-C3BADD3D-4ACD-4B68-BFBE-B480C4AD4764Q36015024-CDCF13CE-1A7C-4BA9-8776-86D8CCD514CFQ36065396-9788EDC0-6850-4651-A4C0-4270E803FCA3Q36302334-0B2A0D6F-40F8-453B-9981-93377C58DFB3Q36354454-9F77B170-3A99-4DB0-83CA-92169E2C2F5FQ36688462-92D92574-AEB1-4A55-AD18-CEF4428D5347Q37566881-84AF5386-1A81-4AC9-87A7-53F11F79144EQ37707179-01F3DCBA-93C9-450D-B576-E75B59B58EB9Q37890936-A94A99EE-6EDE-4C7A-87C2-ACD9970860D1Q38028572-E912FA3F-A19F-44F2-9958-0DA0E1EFE08AQ38119863-9570DDBE-FE92-4A99-88EE-0C728D88748EQ38335199-352D46DD-0A61-4992-A73D-5B8C0EE8491FQ38522796-CF79D11C-D4BF-4576-BA3C-84A99D3CEC02Q38969861-10ECDA95-5088-47D2-9BF0-492EBBAA4418Q40638236-7DBCDDD8-BC81-433C-AE0C-C39097D625F5Q40678150-C475C826-D4C0-4F74-A3EC-C181B3AC3EA4Q41126817-354989B8-B0E2-4CD2-8744-A0AABE889933Q41524241-D453940F-7475-4EFA-BBE2-88B16E71572DQ43922454-FF8EF1C1-DB5D-4C10-8F9E-62E9063F2DE6Q46002738-5D8A4159-C51D-4C72-A3E4-FBC3F5C319CDQ46055970-42CE23B6-9B53-4994-B448-14F489659452Q47567795-2C37F89B-B8C1-4723-9788-306B347113A7
P2860
Primary immunodeficiency diseases due to defects in lymphocytes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Primary immunodeficiency diseases due to defects in lymphocytes.
@ast
Primary immunodeficiency diseases due to defects in lymphocytes.
@en
Primary immunodeficiency diseases due to defects in lymphocytes.
@nl
type
label
Primary immunodeficiency diseases due to defects in lymphocytes.
@ast
Primary immunodeficiency diseases due to defects in lymphocytes.
@en
Primary immunodeficiency diseases due to defects in lymphocytes.
@nl
prefLabel
Primary immunodeficiency diseases due to defects in lymphocytes.
@ast
Primary immunodeficiency diseases due to defects in lymphocytes.
@en
Primary immunodeficiency diseases due to defects in lymphocytes.
@nl
P1476
Primary immunodeficiency diseases due to defects in lymphocytes.
@en
P2093
Buckley RH
P304
P356
10.1056/NEJM200011023431806
P407
P577
2000-11-01T00:00:00Z